DuPont De Nemours (DD) investor relations material

Executive summary

• Net sales for Q2 2026 were $1.8 billion, up 4% year-over-year, driven by organic growth in both segments and favorable currency impacts.

• Operating EBITDA was $448 million, with margin expanding to 24.6%, up 40–80 bps year-over-year.

• Adjusted EPS reached $1.88, up 48% year-over-year and 21% versus prior year pro forma.

• Free cash flow conversion was 127%, reflecting strong working capital discipline.

• Major portfolio actions included the Aramids divestiture, Electronics business separation, and a 1-for-3 reverse stock split effective June 2026.

Financial highlights

• Q2 2026 net sales: $1.819 billion, up 4% year-over-year.

• Operating EBITDA: $448 million, up 8% year-over-year; margin at 24.6%.

• Adjusted EPS: $1.88, up from $1.27 in Q2 2025.

• Transaction-adjusted free cash flow: $326 million, with 127% conversion.

• Healthcare & Water Technologies segment sales: $856 million (+4% organic), EBITDA margin 30.1%; Diversified Industrials: $963 million (+3% organic), EBITDA margin 22.1%.

Outlook and guidance

• Full-year 2026 net sales guidance midpoint: $7.175 billion, organic growth slightly above 4%.

• Operating EBITDA guidance midpoint: $1.76 billion; margin 24.5%.

• Adjusted EPS guidance midpoint: $7.24, up 18% year-over-year.

• Second half 2026 organic growth expected at 6% year-over-year, with Q3 net sales of $1.835 billion and adjusted EPS of $1.80–$1.90.